Evaluation of new apolipoprotein C-II and apolipoprotein C-III automatized immunoturbidimetric kits

Nicolay, Alain; Lombard, Elise; Arlotto, Emmanuelle; Saunier, Vincent; Lorec-Pénet, Anne-Marie; Lairon, Denis; Portugal, Henri

doi:10.1016/j.clinbiochem.2006.04.021

Cited by 6 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total cholesterol, HDL cholesterol and triglycerides levels were measured by the enzymatic colourimetric method (Roche, Meylan, France). LDL cholesterol levels were computed according to Friedewald's formula if triglycerides were < 4.6 mmol ⁄ l. Total plasma apoC-III and apoC-II levels were determined by an automated immunoturbidimetric assay [8]. Anti-human apoC-III and apoC-II polyclonal antibodies from goat were used according to the manufacturer's recommendations (K-Assay; Kamiya Biomedical Company, Seattle, WA, USA).…”

Section: Methodsmentioning

confidence: 99%

Parallel increase of plasma apoproteins C‐II and C‐III in Type 2 diabetic patients

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Parallel increase of plasma apoproteins C‐II and C‐III in Type 2 diabetic patients

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Both fresh and frozen (− 80 • C) sera or plasma samples can be used to measure total apoC-III concentrations. The reference values for total apoC-III concentrations have been quoted as 92.5 + − 33.2 mg/l [36] and 112.2 + − 31 mg/l [37].…”

Section: Measuring Plasma Apoc-iii Concentrations In Plasmamentioning

confidence: 99%

Apolipoprotein C-III: understanding an emerging cardiovascular risk factor

et al. 2008

View full text Add to dashboard Cite

The concurrence of visceral obesity, insulin resistance and dyslipidaemia comprises the concept of the metabolic syndrome. The metabolic syndrome is an escalating problem in developed and developing societies that tracks with the obesity epidemic. Dyslipidaemia in the metabolic syndrome is potently atherogenic and, hence, is a major risk factor for CVD (cardiovascular disease) in these subjects. It is globally characterized by hypertriglyceridaemia, near normal LDL (low-density lipoprotein)-cholesterol and low plasma HDL (high-density lipoprotein)-cholesterol. ApoC-III (apolipoprotein C-III), an important regulator of lipoprotein metabolism, is strongly associated with hypertriglyceridaemia and the progression of CVD. ApoC-III impairs the lipolysis of TRLs [triacylglycerol (triglyceride)-rich lipoproteins] by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. In the circulation, apoC-III is associated with TRLs and HDL, and freely exchanges among these lipoprotein particle systems. However, to fully understand the complex physiology and pathophysiology requires the application of tracer methodology and mathematical modelling. In addition, experimental evidence shows that apoC-III may also have a direct role in atherosclerosis. In the metabolic syndrome, increased apoC-III concentration, resulting from hepatic overproduction of VLDL (very-LDL) apoC-III, is strongly associated with delayed catabolism of triacylglycerols and TRLs. Several therapies pertinent to the metabolic syndrome, such as PPAR (peroxisome-proliferator-activated receptor) agonists and statins, can regulate apoC-III transport in the metabolic syndrome. Regulating apoC-III metabolism may be an important new therapeutic approach to managing dyslipidaemia and CVD risk in the metabolic syndrome.

show abstract

Identification and analysis of anti-HDL scFv-antibodies obtained from phage display based synthetic antibody library

Negi

Lövgren

Malmi

et al. 2016

Clinical Biochemistry

View full text Add to dashboard Cite

Evaluation of new apolipoprotein C-II and apolipoprotein C-III automatized immunoturbidimetric kits

Cited by 6 publications

References 19 publications

Parallel increase of plasma apoproteins C‐II and C‐III in Type 2 diabetic patients

Parallel increase of plasma apoproteins C‐II and C‐III in Type 2 diabetic patients

Apolipoprotein C-III: understanding an emerging cardiovascular risk factor

Identification and analysis of anti-HDL scFv-antibodies obtained from phage display based synthetic antibody library

Contact Info

Product

Resources

About